Achieving regulatory and payer approval for drug discovery is becoming increasingly difficult. You need to have evidence of effectiveness at every stage of the clinical trial – but how do you build a robust argument?
There are a number of common reasons why drug applications are not approved, often due to lack of certainty around clinical benefits, costs, safety and insufficient trial design.
The price of failure is rising rapidly, which is why evidence reviews can strengthen the value differentiation and communication at every stage of the development process. Early stage reviews help establish value and late evidence provides crucial data required for reimbursement agencies.
Regular reviews also highlight any gaps in evidence and ultimately help pave the road to market.